Verition Fund Management
LCTX icon

Verition Fund Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Verition Fund Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-42,304
Closed -$59.6K – 2521
2023
Q2 		$59.6K Buy
+42,304
New +$58.5K ﹤0.01% 2024
2023
Q1 		– Sell
-10,400
Closed -$12.2K – 2378
2022
Q4 		$12.2K Buy
+10,400
New +$13.1K ﹤0.01% 1947

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Verition Fund Management's LCTX Position: Q3 2023 in Review

Verition Fund Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2023, closing a stake of 42,304 shares — an estimated $59.6K sold.

Verition Fund Management first reported a position in LCTX in Q4 2022 and held it in 2 quarters. The position peaked at $59.6K in Q2 2023. 104 funds tracked by Wall St. Rank hold LCTX as of Q3 2023.

  • Verition Fund Management reported no remaining Lineage Cell Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 42,304 Lineage Cell Therapeutics shares in Q3 2023, an estimated $59.6K.
  • Verition Fund Management first reported a position in Lineage Cell Therapeutics in Q4 2022 and held it in 2 quarters.
  • Verition Fund Management's Lineage Cell Therapeutics position peaked at $59.6K in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.